Precision's one-time gene editing treatment lowers cholesterol in monkeys for 3 years

Precision BioSciences was founded in 2006 to develop a genome editing technology that uses homing nucleases to make precise edits in DNA. Now, the company has preclinical evidence showing that the approach—designed as a one-time treatment—holds promise for treating familial hypercholesterolemia, high cholesterol that’s caused by abnormalities in the gene PCSK9.